Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz Sells 9,102 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 9,102 shares of Mirum Pharmaceuticals stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $438,898.44. Following the completion of the transaction, the chief executive officer now directly owns 115,920 shares of the company’s stock, valued at $5,589,662.40. The trade was a 7.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Christopher Peetz also recently made the following trade(s):

• On Friday, January 24th, Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.92, for a total value of $327,629.04.
• On Tuesday, January 7th, Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total value of $320,678.98.

Mirum Pharmaceuticals Stock Up 3.3 %

Shares of NASDAQ:MIRM opened at $50.21 on Wednesday. The company has a 50 day moving average price of $44.39 and a two-hundred day moving average price of $42.02. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The company has a market capitalization of $2.41 billion, a PE ratio of -24.86 and a beta of 0.96. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $50.34.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $90.38 million for the quarter, compared to analysts’ expectations of $81.99 million. During the same quarter in the prior year, the business posted ($0.57) EPS. The business’s revenue was up 89.4% compared to the same quarter last year. Analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.44 earnings per share for the current year.

Institutional Trading of Mirum Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after buying an additional 318 shares in the last quarter. R Squared Ltd purchased a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth approximately $69,000. Avanza Fonder AB purchased a new stake in shares of Mirum Pharmaceuticals in the fourth quarter worth $189,000. Y Intercept Hong Kong Ltd bought a new position in Mirum Pharmaceuticals during the third quarter valued at approximately $215,000. Finally, Creative Planning purchased a new position in shares of Mirum Pharmaceuticals in the 3rd quarter worth approximately $249,000.

Wall Street Analysts Forecast Growth

MIRM has been the topic of several recent research reports. Leerink Partners increased their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Citigroup increased their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, HC Wainwright reissued a “buy” rating and set a $66.00 price target on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $57.10.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.